Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with
metastatic breast cancer and triple negative breast cancer. PMD-026 is a targeted oral agent
designed to kill tumor cells in metastatic breast cancer and triple negative breast cancer.